Opinion
Video
Unmet Needs and Treatment Considerations in Managing AL Amyloidosis
A panel of expert oncologists examine current unmet needs in the treatment landscape for AL amyloidosis.
This is a video synopsis/summary of a Peer Exchange involving Heather Landau, MD; Vaishali Sanchorawala, MD; and Jeffrey Zonder, MD.
Panelists address key unmet medical needs in light chain (AL) amyloidosis. They highlight the urgency for early diagnosis, emphasizing awareness and education, especially for distinguishing the disease from multiple myeloma. The discussion stresses the need for specialized care for patients with advanced cardiac involvement who are excluded from current clinical trials.
Another crucial unmet need is the absence of validated criteria for relapsed and refractory cases, leading to uncertainties in reinitiating therapy. Lastly, the speakers emphasize the necessity for licensed antifibril agents to remove amyloid deposits from organs. They suggest exploring various targets in the fibrogenesis pathway for a comprehensive therapeutic approach. They acknowledge the challenge of fully reversing organ damage, particularly in advanced cases, highlighting the intricate nature of treating AL amyloidosis.
Video synopsis is AI-generated and reviewed by OncLive® editorial staff.
